Pyrotinib

• CAT Number: I008931
• CAS Number: 1269662-73-8
• Molecular Formula: C32H31ClN6O3
• Molecular Weight: 583.089
• Purity: ≥95%
• Target: EGFR inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• Related CAS: 1397922-61-0
• IUPAC Name: (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide
• InChI: InChI=1S/C32H31ClN6O3/c1-3-41-30-17-27-25(16-28(30)38-31(40)12-10-24-8-6-14-39(24)2)32(21(18-34)19-36-27)37-22-9-11-29(26(33)15-22)42-20-23-7-4-5-13-35-23/h4-5,7,9-13,15-17,19,24H,3,6,8,14,20H2,1-2H3,(H,36,37)(H,38,40)/b12-10+/t24-/m1/s1
• InChIKey: SADXACCFNXBCFY-IYNHSRRRSA-N
• SMILES: O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(OCC4=NC=CC=C4)C(Cl)=C3)C2=C1)/C=C/[C@@H]5N(C)CCC5

Pyrotinib (CAT: I008931), also known as SHR-1258, is a dual kinase inhibitor targeting both the epidermal growth factor receptor (EGFR or HER-1) and the human epidermal growth factor receptor 2 (ErbB2 or HER-2). It is administered orally and exhibits potential antineoplastic activity. Pyrotinib works by binding to and inhibiting the activity of EGFR and HER2, leading to the inhibition of tumor growth, angiogenesis, and regression in tumor cells expressing these receptors. EGFR and HER2 are receptor tyrosine kinases that are overexpressed in various tumor types, playing critical roles in tumor cell proliferation and the development of tumor blood vessels. Pyrotinib’s dual inhibition of EGFR and HER2 makes it a promising candidate for targeted cancer therapy.

Overview of Clinical Research

Pyrotinib is an ERBB 2 receptor antagonist. The Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in Belgium (PO) (EudraCT2020-000951-11) are ongoing.

Reference

1:Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J, Luo Y, Xing P, Lan B, Li M, Yi Z, Cai R, Yuan P, Zhang P, Li Q, Xu B.J Clin Oncol. 2017 May 12:JCO2016696179. doi: 10.1200/JCO.2016.69.6179. [Epub ahead of print] PMID: 28498781
2:Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L, Chen X, Zhong D, Lou L, Tao W, Zhang L.Eur J Pharm Sci. 2017 Jan 21. pii: S0928-0987(17)30043-X. doi: 10.1016/j.ejps.2017.01.021. [Epub ahead of print] PMID: 28115222
3:Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. Zhu Y, Li L, Zhang G, Wan H, Yang C, Diao X, Chen X, Zhang L, Zhong D.J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Oct 15;1033-1034:117-27. doi: 10.1016/j.jchromb.2016.08.009. Epub 2016 Aug 7. PMID: 27541626